CHICAGO, IL and FORT WORTH, TX, October 18, 2022 – Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced the addition of eminent cancer research leaders Roger B. Cohen, MD, Lee M. Ellis, MD, and John L. Marshall, MD to their Scientific Advisory Board. Dr. Roger …
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient …
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate …
Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate inCombination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met …
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for treatment of patients with pancreatic cancer. 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being …
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small …
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PANCREATIC CANCER Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May 29th, 2020. Dr. …
ACTUATE THERAPEUTICS ANNOUNCES 9-ING-41 DATA PRESENTATION AT ASCO ANNUAL MEETING 2020 Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the initiation of two additional clinical studies with its lead molecule, 9-ING-41, a Glycogen Synthase Kinase beta (GSK-3β) inhibitor. On April 8, the company opened its 1902 study: A Phase 1 study of 9-ING-41, a Glycogen Synthase …
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41 Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised an additional $6.5M in a Series B-3 financing round. This Series B-3 was led by Bios Partners with Kairos Ventures, DEFTA Partners, and other existing investors participating, and brings total funding for Actuate’s Series B …
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round. The Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and existing investors, Bios Partners, participating. Actuate will use the proceeds of the …
ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING Read More »
